Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725712 · ClinicalTrials.gov registry record · Phase 2
Study of GSK1363089 in Metastatic Gastric Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00725712 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 74 participants.
The verdict
NCT00725712, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
Interventions
- DRUG GSK1363089 (formerly XL880)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2007-03-31 |
| Est. Completion | 2009-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725712
The ClinicalTrials.gov registry entry for NCT00725712 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1363089 (formerly XL880) is the first listed.
NCT00725712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00725712 about?
NCT00725712 is a clinical study titled "Study of GSK1363089 in Metastatic Gastric Cancer". This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
What is the current status of trial NCT00725712?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2007-03-31. Estimated completion is 2009-11-30.
What interventions are being tested in trial NCT00725712?
The interventions under investigation include: GSK1363089 (formerly XL880) (DRUG).
Who is sponsoring clinical trial NCT00725712?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.